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IL-17+ CD8+ T cell suppression by dimethyl
fumarate associates with clinical response in
multiple sclerosis
Christina Lückel et al.#
IL-17-producing CD8+ (Tc17) cells are enriched in active lesions of patients with multiple
sclerosis (MS), suggesting a role in the pathogenesis of autoimmunity. Here we show that
amelioration of MS by dimethyl fumarate (DMF), a mechanistically elusive drug, associates
with suppression of Tc17 cells. DMF treatment results in reduced frequency of Tc17, contrary
to Th17 cells, and in a decreased ratio of the regulators RORC-to-TBX21, along with a shift
towards cytotoxic T lymphocyte gene expression signature in CD8+ T cells from MS patients.
Mechanistically, DMF potentiates the PI3K-AKT-FOXO1-T-BET pathway, thereby limiting IL-
17 and RORγt expression as well as STAT5-signaling in a glutathione-dependent manner. This
results in chromatin remodeling at the Il17 locus. Consequently, T-BET-deﬁciency in mice or
inhibition of PI3K-AKT, STAT5 or reactive oxygen species prevents DMF-mediated
Tc17 suppression. Overall, our data disclose a DMF-AKT-T-BET driven immune modulation
and suggest putative therapy targets in MS and beyond.
https://doi.org/10.1038/s41467-019-13731-z OPEN
#A full list of authors and their afﬁliations appears at the end of the paper.
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Multiple sclerosis (MS) is an inﬂammatory disease of thecentral nervous system (CNS) that affects ~2.5 millionpeople worldwide causing neurological disability pre-
dominantly in young women. The disease is believed to be
mediated by self-reactive T cells which initiate and perpetuate
inﬂammation characterized by perivascular immune cell inﬁl-
tration, demyelination, neuroaxonal damage and inﬂammatory
lesions1,2. In support of this assumption the largest group of
genes associating with MS susceptibility is involved in antigen
presentation to T cells or in T cell pathways3–5. Moreover, both
CD4+ and CD8+ T cells are present in MS lesions1,2,6 and T cell
inﬁltration correlates with the activity of demyelinating lesions7.
Notably, CD8+ T cells are found in higher frequency than CD4+
T cells8–10 and primarily among CD8+ T cells large clonal
expansions have been reported in active demyelinating MS
lesions11. IL-17-producing CD8+ (Tc17) are enriched in cere-
brospinal ﬂuid (CSF) in early MS12 and Tc17 frequencies in CSF
correlate with disability13. Furthermore, increased frequencies of
Tc17 cells were detected in peripheral blood (PB) of MS patients
as compared to healthy controls14 and Tc17 cells were present in
active areas of acute and in chronic MS lesions alongside with IL-
17-producing CD4+ (Th17) T cells15, implicating a contribution
of both subpopulations to MS pathogenesis. Interestingly, many
of IL-17-producing CD8+ T cells in MS patients bear features of
mucosal associated invariant T (MAIT) cells, which are MHC-
related protein 1 (MR1)-restricted CD8+ T cells dependent on
commensal microbiota6,16–20. Functionally, using experimental
autoimmune encephalomyelitis (EAE) as a pre-clinical mouse
model for MS, we showed that Tc17 cells provided “reverse help”
for the encephalogenicity of IL-17-producing CD4+ T (Th17)
cells via their hallmark cytokine IL-17A12, revealing an important
Tc17-dependent enhancement of Th17-mediated autoimmunity
of the CNS.
Tc17 cells are induced by the cytokines IL-6 and transforming
growth factor (TGF)-β, and require the type 17-related tran-
scriptional regulator RORγt21. In contrast to “canonical” cyto-
toxic T lymphocytes (CTLs), Tc17 cells are non-cytotoxic and
express diminished levels of the CTL-speciﬁc transcription factors
T-BET and EOMES, which counter regulate their differentia-
tion22–24. In addition to MS, Tc17 cells are also involved in the
pathology of psoriasis21, an autoimmune disease of the skin.
Dimethyl fumarate (DMF) is an efﬁcient immunomodulatory
drug, applied in MS and psoriasis; however, to date the
mechanism of its beneﬁcial action has remained unclear25. It is
known that DMF succinates kelch-like ECH-associated protein 1
(KEAP1), leading to the activation of nuclear factor erythroid 2-
related factor 2 (NRF2). Although this pathway is believed to
protect astrocytes and neurons by inducing an anti-oxidative
response25, data from NRF2-deﬁcient mice suggested NRF2-
independent mechanisms in the anti-inﬂammatory activity of
DMF26. Indeed, succination of GAPDH by DMF suppressed
aerobic glycolysis in myeloid and lymphoid cells, thereby limiting
autoimmunity27,28. Finally, succination of the reactive oxygen
species (ROS) scavenger glutathione (GSH) reduced its anti-
oxidant capacity thus upregulating endogenous ROS in DCs,
tumor cells, monocytes and macrophages29–32. In line with these
data, an increase in ROS was observed in monocytes and T cells
from MS patients upon DMF therapy32,33. ROS display
concentration-dependent effects on T cells ranging from activa-
tion at physiological levels to inhibition of function at sustainably
upregulated concentrations34,35.
Considering the central contribution of T cells to CNS
pathology and the efﬁcacy of DMF treatment in MS36, we
hypothesized that DMF may target them. We therefore analyzed
cytokine production and molecular changes in T cells in response
to DMF therapy in patients and in the mouse model EAE. Our
analyses identiﬁed Tc17 cells as a target cell population of DMF.
We deﬁne critical pathways including PI3K-AKT-FOXO1-T-BET
and STAT5 leading to histone modiﬁcations, which control this
process in a GSH-dependent manner. Thus, our data suggest a
new rational approach for targeting Tc17 cells in MS and other
IL-17-mediated disorders.
Results
Tc17 suppression accompanies positive response to DMF in
MS. To understand a relation between frequencies of IL-17-
producing CD4+ or CD8+ T cells and a response to DMF, we
analyzed 72 cryopreserved peripheral blood mononuclear cell
(PBMC) samples isolated from peripheral blood (PB) of a cohort
of 36 patients with MS before and after initiation of DMF ther-
apy, which did (responders, n= 18) or did not fulﬁll (non-
responders n= 18) no evidence of disease activity-3 (NEDA-3)
criteria after about one year of treatment (Supplementary Fig. 1a,
Supplementary Tables 1–3). NEDA-3 is a clinically relevant
composite score reﬂecting therapeutic efﬁciency37 deﬁned as: (i)
no relapses, (ii) no sustained disability progression measured with
the expanded disability status scale (EDSS) and (iii) no new/
enlarging T2-weighted lesions in magnetic resonance imaging
(MRI). Baseline samples and samples obtained after DMF therapy
originated from the same patients.
For the analysis, frozen PBMCs were thawed and stained
(Supplementary Fig. 1a, b). The change in the abundance of IL-
17-producing CD8+ T (Tc17) cells before versus after therapy
initiation distinguished responders versus non-responders
(Fig. 1a). Interestingly, the patients who responded to the
therapy showed a signiﬁcantly lower Tc17 frequency after
treatment as compared to the therapy initiation, while in non-
responders the frequency of Tc17 cells was not signiﬁcantly
changed. This was in contrast to IL-17-producing CD4+ T
(Th17) cells which were not differentially abundant before and
after the start of the therapy in responders as well as in non-
responders (Fig. 1a). Notably, at the therapy start, responders
harbored higher frequencies of Tc17 cells as compared to non-
responders, whereas Th17 cell abundance was not signiﬁcantly
different in the analyzed patient cohort (Fig. 1b, Supplementary
Fig. 1c). These results suggested inhibition of Tc17 cells as a
possible mechanism of DMF therapy. Indeed, DMF suppressed
IL-17 in human Tc17 cells cultured in vitro, indicating a direct
effect (Supplementary Fig. 1d). This inhibition was likely
dependent on ROS, as the ROS-scavenger glutathione (GSH)
restored IL-17 production as examined by intracellular staining
and ELISA (Supplementary Fig. 1d, e). Likewise, DMF inhibited
IL-17 in murine Tc17 cells in a ROS-dependent manner, as GSH,
its precursor N-acetyl-L-cysteine (NAC) or Trolox, a vitamin E
derivative and GSH-independent ROS scavenger, reversed the
altered cytokine production (Fig. 1c and Supplementary Fig. 1f),
suggesting a similar regulation of IL-17 in Tc17 cells by DMF
across mice and humans.
As expected, DMF mediated a profound depletion of GSH
(Fig. 1d) as measured by a signiﬁcantly reduced GSH/GSSG ratio.
This resulted in upregulation of endogenous ROS in Tc17 cells, as
detected by staining with CM-H2DCFDA (Fig. 1e), which was
reversed by the addition of GSH, conﬁrming that its depletion
mediates the upregulation of ROS. Notably, at concentrations of 20
µM, which efﬁciently suppressed IL-17 production in murine Tc17
cells (Fig. 1c), DMF did not cause appreciable cell death, whereas in
line with published reports33,38, higher concentrations did (Supple-
mentary Fig. 1g). Importantly, addition of GSH reversed the cell
death (Supplementary Fig. 1g), suggesting a dose-dependent effect
of DMF relating to GSH-depletion, which suppressed IL-17 at
moderate levels, whereas at higher triggered cell death. Although
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DMF reduced proliferation of Tc17 cells in a GSH-dependent
manner, this was not the cause for the reduced IL-17 production,
since the frequencies of IL-17-producing cells were reduced in each
proliferation cycle (Supplementary Fig. 1h, i).
As IL-23 is important for the pathogenicity of Th17 cells6, we
performed analysis of the DMF effects on Th17 cells cultured
under pathogenic conditions including IL-23. Similar to Tc17
cells, DMF treatment led to signiﬁcant ROS upregulation in
pathogenic Th17 cells (Fig. 1f). However, this did not result in a
statistically signiﬁcant reduction of IL-17 (Fig. 1g), suggesting that
Tc17 are particularly responsive to DMF-mediated GSH deple-
tion. In line with a recent report showing that DMF inhibits
glycolysis by succination of GAPDH28, DMF suppressed
glycolytic capacity also in Tc17 cells (Fig. 1h). However, IL-17
production by Tc17 cells was rather independent of glycolysis
since the inhibitor 2-deoxy-D-glucose (2-DG) upregulated IL-17
while downregulating IFN-γ (Fig. 1i and Supplementary Fig. 1j).
In contrast to Th17 cells, which depend on glycolysis39, IL-17
production by Tc17 cells relied on oxidative phosphorylation
(OXPHOS), as the inhibitors rotenone or oligomycin signiﬁcantly
suppressed the IL-17 production (Fig. 1j). Overall these data
indicate that DMF preferentially targets Tc17 cells in a ROS- and
GSH-dependent manner, probably by a different mechanism as
compared to Th17 cells.
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DMF decreases RORC-to-TBX21 ratio in memory CD8+
T cells. To identify the impact of DMF at a genome-wide level we
performed RNA-Sequencing (RNA-Seq) of murine Tc17 cells
treated with DMF alone or in combination with GSH. Among
281 transcripts highly signiﬁcantly regulated by DMF (p adj <
0.01, log2FC ≥ 0.75), genes associated with type 17 T cells,
including Il17a, Il17f, Il21, Rorc, and Ccr6, were downregulated,
whereas the effector cytotoxic T lymphocyte (CTL) signature
genes, Ifng, Gzmb, Gzmc, Prf1, and Tbx2140, were upregulated
(Fig. 2a). This was reﬂected by a decreased ratio of RORγt-to-T-
BET at mRNA and protein levels (Fig. 2b, c). Both, positive and
negative effects on gene transcription were reversed to a strong
extent by the addition of GSH (Fig. 2a–c, Supplementary Fig. 2a),
conﬁrming a marked dependency on GSH-depletion. Gene set
enrichment analysis (GSEA)41 revealed that Tc17 signature genes
were downregulated by DMF, while genes associated with effector
CTL signature, were upregulated (Fig. 2d, e). Hence, DMF pro-
motes a transcriptional shift of Tc17 cells towards a “CTL-like”
transcriptional signature.
To elucidate whether the above described DMF effect also
applied to human disease, we performed RNA-Seq of memory
CD45RA−CD8+ T cells from PB of MS patients, which were not
treated with DMF (“DMF-untreated”, n= 4) or treated with
DMF (“DMF-treated” n= 4) fulﬁlling NEDA-3 criteria after one
year of therapy (Supplementary Fig. 2b, Supplementary Table 4).
Principal component analysis (PCA) analysis of the top 20,000
genes clearly separated patients before and after DMF (Supple-
mentary Fig. 2c). Upon DMF treatment 3840 transcripts were
differentially expressed (DE) in human CD8+ T cells (p adj < 0.1),
965 transcripts of which were also differentially expressed in
mouse Tc17 cells upon DMF treatment (Fig. 2f). Within the
concordantly upregulated genes (Fig. 2g, upper right quadrant),
we found transcripts associated with the effector CTL signature,
GZMB, IFNG, PRF1 and TBX21, whereas Tc17 signature genes
RORC, CCR6, IL23R, RORA were downregulated accordingly
(Fig. 2g lower-left, Supplementary Fig. 2d). Indeed, comparison of
the top DE genes in the mouse with the human dataset revealed
similar expression patterns for the majority of genes, including
Tc17 and effector CTL signatures genes (Fig. 2h). Accordingly,
similar to mouse data, the ratio of RORC-to-TBX21, was
signiﬁcantly reduced in DMF-treated human CD8+CD45RA−
T cells (Fig. 2i). This shift was likely regulated by ROS, as the ROS
pathway was upregulated in memory CD8+ T cells after one year
of positive response to DMF as compared to therapy start (Fig. 2j
and Supplementary Fig. 2e). Next, we compared memory CD8+
T cells from MS patients to the IL-17+CD8+ and IL-17−CD8+
T cells from healthy individuals, which characteristic
transcriptional proﬁles were recently determined42. Differentially
expressed genes (p adj < 0.0.05) speciﬁc for IL-17+CD8+ T cell or
IL-17−CD8+ T cell proﬁle distinguished DMF-treated versus
untreated MS patients. Interestingly, CD8+ T cells from
untreated patients exhibited more similarity to IL-17+CD8+
T cells than cells from DMF-treated patients, which in turn were
more similar to IL-17−CD8+ T cells, corroborating the idea on
DMF-mediated diversion of Tc17 towards a “CTL-like” tran-
scriptional signature (Fig. 2k, l, Supplementary Fig. 2f, g).
PI3K-AKT-T-BET axis suppresses IL-17 and RORγt in Tc17
cells. Analysis of pathways involved in a positive response to
DMF therapy (deﬁned as fulﬁllment of NEDA-3 criteria) in
memory CD8+ T cells from MS patients revealed a signiﬁcant
enrichment for genes associated with the PI3K-AKT-mTOR-
pathway (Fig. 3a and Supplementary Fig. 3a) (GSEA, MSigDB,
hallmark dataset). Indeed, inhibition of PI3K activity by the
inhibitor Ly294002 resulted in partial restoring of IL-17 pro-
duction in DMF-treated murine Tc17 cells (Fig. 3b), suggesting
that enhanced PI3K-signaling in DMF-treated Tc17 cells con-
tributed to IL-17 suppression. Furthermore, downstream of PI3K,
phosphorylation of AKT43 at S473 as well as at T308 (Fig. 3c, d)
was enhanced by DMF, GSH-dependently.
AKT phosphorylates the transcription factor FOXO1 to
inactivate its transcriptional activity44. Consistent with this
notion, DMF increased FOXO1/3a phosphorylation, accompa-
nied by the downregulation of FOXO1 targets (Fig. 3e, f). FOXO1
is a suppressor of T-BET44,45 and T-BET was upregulated in
DMF-treated Tc17 cells (Fig. 2c). We therefore speculated that
DMF-mediated suppression of IL-17 was dependent on AKT-
dependent FOXO1 inactivation, leading to upregulation of
T-BET. To test this hypothesis, we compared the susceptibility
of T-BET-deﬁcient (Tbx21−/−) and wildtype (WT) Tc17 cells to
treatment with DMF and a selective AKT-1/2 inhibitor (AKTi)46.
AKTi boosted IL-17 production signiﬁcantly in DMF-treated WT
Tc17 cells (Fig. 3g, upper). In contrast, the impaired IL-17
production in DMF-treated Tbx21−/− Tc17 cells was refractory to
AKTi treatment (Fig. 3g, lower), indicating that T-BET is
required for AKT-mediated IL-17 suppression. Furthermore,
DMF failed to inhibit RORγt and was less effective in suppressing
IL-17 in Tbx21−/− as compared to WT cells (Fig. 3h, i). Contrary
to Tc17 cells, AKTi in combination with DMF inhibited IL-17
production in pathogenic Th17 cells (Supplementary Fig. 3b).
Another target of PI3K-AKT signaling is mTORC143. DMF
treatment resulted in an enrichment of mTOR-associated
transcripts in CD8+ T cells from MS patients and in murine
Fig. 1 Suppression of IL-17A production in CD8+ T cells by DMF is ROS-dependent. a Flow cytometry of IL-17A in CD8+CD45RA− or CD4+CD45RA−
cells from blood of the same MS patients before and after DMF therapy fulﬁlling (reponders, n= 18), or not (non-responders, n= 18) NEDA-3 criteria after
treatment (Supplementary Tables 1-3, Supplementary Fig. 1a, b). The observer was blinded to experimental groups. b Frequency of CD8+CD45RA−IL-17A+
cells before DMF therapy in responders and non-responders. c-j Naive CD62L+CD44−CD8+ or CD62L+CD44−CD4+ T cells from WT mice were
primed with anti-CD3/CD28 antibodies and TGF-β+ IL-6+ IL-2 (murine Tc17) or TGF-β+ IL-6+ IL-23+ IL-2 (murine Th17), in the presence of DMSO
(Ctrl), 20 µM DMF or 20 µM DMF+ 50 µM GSH (DMF+GSH) or 20 µM DMF+ 1 mM NAC or ± 250 µM 2-DG or ± 10 nM Rotenone or ± 15 nM
Oligomycin. c, g, i, j Flow cytometry of IL-17A in Tc17 c, i, j or Th17 cells g differentiated for 72 h with indicated treatment. d Ratio of reduced to oxidized
glutathione (GSH/GSSG) contents in Tc17 cells differentiated for 2 h. e, f Flow cytometry of ROS levels in Tc17 or Th17 f cells differentiated for 2 h
determined by CM-H2DCFDA staining (fold of geometric mean ﬂuorescence intensity (MFI), normalized to the corresponding control, which was
arbitrarily set to 1. h Extracellular acidiﬁcation rates (ECAR) and glycolytic capacity of Tc17 cells ± DMF after addition of 10mM Glucose, 2.5 µM
Oligomycin and 100mM 2-DG. Bars show mean ± s.d. from seven e, or ﬁve c, d, i, or four to three f, g, j combined experiments, or one representative with
9 replicates of four experiments h; individual values are plotted. P-values in a from the same patient by two-tailed, paired t-test, while for the change in
percentages CD8+CD45RA−IL-17+ or CD4+CD45RA−IL-17+ after DMF treatment by two-tailed, unpaired t-test (value between responders and non-
responders), in b P value and in g, h ***p < 0.05 or non-signiﬁcant (ns), by two-tailed, unpaired t-test, f *p < 0.05 by two-tailed, unpaired t-test with
Welch’s correction, c, i, j ***p < 0.001, ****p < 0.0001 by one-way ANOVA followed by Tukey’s Honestly Signiﬁcant Difference (HSD) multiple comparison
test, in d, e *p < 0.05, **p < 0.01, ***p < 0.001 by one-way Welch’s ANOVA with Games–Howell multiple comparison test.
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Tc17 cells (Supplementary Fig. 3c, d). Furthermore, DMF
enhanced the mTORC1-dependent phosphorylation of the
ribosomal protein S6 at S235/236 in murine Tc17 cells
(Supplementary Fig. 3e). In line with published data39, inhibition
of mTOR signaling by rapamycin blocked IL-17 production in
pathogenic Th17 cells (Supplementary Fig. 3f), in contrast to
Tc17 cells in which rapamycin did not impact IL-17 (Supple-
mentary Fig. 3g).
In summary, these data reveal a crucial role of the PI3K-AKT-
FOXO1 pathway in the DMF-mediated IL-17 suppression as well
as in the shift in RORγt-to-T-BET ratio and indicate differential
roles of AKT and mTOR signaling in IL-17 regulation by Tc17
and Th17 cells.
STAT5 contributes to inhibition of IL-17 in Tc17 cells. Deeper
analysis of the transcriptional proﬁling data revealed an enrich-
ment of IL-2-STAT5 signaling-associated genes in DMF-treated
murine Tc17 cells, which was GSH-dependent (Fig. 4a and
Supplementary Fig. 4a). In line with a role for this pathway, DMF
inhibited IL-17 production in Tc17 cells only in the presence of
IL-2, in a dose-dependent manner (Fig. 4b, c). However, neither
GSH depletion nor ROS upregulation were dependent on the
presence of IL-2 (Fig. 4d, e). Thus, DMF-induced GSH depletion,
which correlates with ROS upregulation suppressed IL-17 pro-
duction by enhancing IL-2 signaling.
IL-2 signaling involves several pathways, including activation
of PI3K-AKT and activation of STAT547, which inhibits IL-17
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production in Th17 cells48. DMF upregulated IL-2-mediated
STAT5 phosphorylation GSH-dependently (Fig. 4f), and retro-
viral overexpression of constitutively active STAT5 revealed that
STAT5 suppressed IL-17 production in Tc17 cells (Fig. 4g and
Supplementary Fig. 4b, c). Conversely, inhibition of STAT5
function by a pharmacological inhibitor partially restored IL-17
production (Fig. 4h). These data indicate that DMF acts on IL-2
signaling, involving both PI3K-AKT-T-BET and STAT5 path-
ways to suppress IL-17 production in Tc17 cells (Fig. 4i).
DMF drives epigenetic remodeling at the Il17 locus. Histone
modiﬁcations at gene regulatory elements undergo dynamic
changes that correlate with gene expression proﬁles49. Since DMF
limited IL-17 in Tc17 cells, we speculated on accompanying
changes in the epigenetic landscape. Indeed, DMF suppressed
permissive H4Ac as well as H3K27Ac on Il17 promoter and
enhancer-5 (Fig. 5a), partially in GSH-dependent manner. In
contrast, neither the global histone acetylation nor the Il10 pro-
moter were affected, indicating a speciﬁc suppression of the Il17
locus (Fig. 5b and Supplementary Fig. 5a). Since IL-2 signaling
depends on histone deacetylases (HDACs)50, and DMF inhibited
IL-17 in IL-2-dependent manner, we assumed an inﬂuence of
DMF-triggered pathway on HDACs. The inhibitor of class I and
II of mammalian HDACs, trichostatin A (TSA), neutralized the
inhibitory effect of DMF on IL-17 production to some extent
(Supplementary Fig. 5b), indicating a partial involvement of type
I or II HDACs in DMF-driven suppression of histone acetylation
on the Il17 locus.
Furthermore, permissive H3K4me3 on the Il17a promoter, as
well as to some extent on the Il17 enhancer-5 was suppressed by
DMF treatment (Fig. 5c), while the H3K4me3 on rpl32 promoter
or repressive H3K27me3 were not signiﬁcantly altered (Fig. 5d
and Supplementary Fig. 5c–e). Thus, DMF-signaling leads to
suppression of permissive histone modiﬁcations on the Il17 locus.
DMF impairs the pathogenicity of Tc17 cells in EAE. To test the
impact of DMF in vivo, we induced EAE in WT mice and treated
them with DMF by oral gavage starting from disease onset (day 8,
therapeutic setting) or in drinking water staring ten days before
immunization (preventive setting) (Supplementary Fig. 6a, b).
Therapeutic DMF application signiﬁcantly reduced EAE severity,
reﬂected by reduced T cell and CD8+ T cell numbers, as well as by
decreased frequency of Tc17 cells in the CNS (Fig. 6a-d). Con-
sistent with the literature26,29, preventive DMF treatment likewise
reduced EAE severity (Supplementary Fig. 6c). This was accom-
panied by signiﬁcantly decreased percentages of Tc17 cells in CNS
(Supplementary Fig. 6d), in accordance with the data obtained in
the therapeutic setting (Fig. 6d). Thus, therapeutic and preventive
DMF application caused EAE amelioration accompanied by a
reduction in the Tc17 cell abundance. To investigate DMF effects
speciﬁcally on Tc17 cells, we applied an adoptive transfer EAE
model involving the cooperating Tc17 and Th17 cells, in which
Tc17 cells via IL-17A provide “reverse help” for CNS pathogeni-
city of Th17 cells12. To this end, we transferred sub-pathogenic
numbers of 2D2 CD4+ T cells, which are transgenic for myelin
oligodendrocyte glycoprotein (MOG)-speciﬁc Vβ11+/Vα3.2+
TCR together with congenic polyclonal Tc17 cells into Irf4−/−
mice, which are resistant to EAE12,51. Tc17 cells were treated with
DMF or control during in vitro differentiation. Transfer of 2D2
cells alone did not evoke disease, while the combination of 2D2
cells with Tc17 cells caused early onset and severe disease course
(Fig. 6e). This was accompanied by a prominent T cell inﬁltration
into the CNS, including endogenous and transferred CD8+ T cells
(Fig. 6f, g). Transferred Tc17 cells were detectable in draining LNs
and correlated with CNS-inﬁltration of CD4+ T cells producing
IL-17 at higher proportions as compared to transferred 2D2 cells
alone (Fig. 6h–k). In contrast, co-transfer of 2D2 cells together
with DMF-treated Tc17 cells failed to evoke severe EAE and the
total T cell and CD8+ T cell inﬁltration into the CNS was strongly
reduced (Fig. 6e–g). Accordingly, transferred DMF-treated Tc17
cells produced less IL-17 in draining LNs and failed to upregulate
IL-17 production by CNS inﬁltrating CD4+ T cells (Fig. 6h–k).
Hence, DMF treatment caused a loss of the Tc17-dependent Th17
pathogenicity and conferred a stable “low IL-17” phenotype to
Tc17 cells, suggesting a mechanism for amelioration of auto-
immunity in CNS upon DMF treatment.
Discussion
Over the past decades, several MS-modifying drugs have been
approved for treatment. This includes orally applied DMF, which
alleviates disability progression and has good safety and toler-
ability25. DMF reduced the annual relapse rate by 53% and
relative risk reduction of disability progression by 38%36, indi-
cating its efﬁciency. However, a considerable proportion of
patients do not respond to DMF therapy, indicating a need for
stratiﬁcation of patients. Although DMF has been shown to act
on different cell types including microglia, neurons, dendritic
cells, macrophages and to some extent CD4+ T cells, it is still not
known how this drug reduces overall disease activity25. Therefore,
a close mechanistic understanding of the inﬂuence of DMF on
target cells can contribute to a development of markers and an
improvement of its clinical efﬁcacy.
IL-17A plays an important role in the autoimmune-patho-
genesis, since (i) increased numbers of IL-17+ CD4+ and CD8+
T cells are detectable in active as compared to inactive areas of
MS lesions15, (ii) genetic risk factors related to IL-23-IL-17 axis
Fig. 2 Diversion of Tc17 cells towards a “CTL-like” genetic signature upon DMF treatment. a RNA-Seq based heatmap of 281 differentially expressed
(DE) genes (p adjusted [p adj] < 0.01 and log2FC≥ 0.75) between Ctrl ± DMF or DMF+GSH-treated murine Tc17 cells differentiated for 48 h (n= 3).
Highlighted are genes associated with type 17 or CTL signature. b Expression-ratio of Rorc-to-Tbx21 calculated from RNA-Seq from a, normalized to the DMF
values, which were arbitrarily set to 1. c Flow cytometry of RORγt or T-BET in murine Tc17 cells differentiated for 72 h, to the right, ratio of RORγt-to-T-BET
calculated from fold MFI. d, e GSEA of genes associated with Tc17 d or CTL e phenotype as deﬁned by GSE110346 in Tc17 cells from a. f Venn diagram of
DMF-dependent DE genes in murine Tc17 (dataset from a) and human CD8+CD45RA− T cells from matched groups of MS patients “DMF untreated” (n=
4) and “DMF treated” (n= 4), who fulﬁlled NEDA-3 criteria after 12–13 months of DMF therapy (Supplementary Table 4 and Supplementary Fig. 2b) based
on RNA-Seq (p adj < 0.1). g Scatter plot of overlapping gene regulation in murine Tc17 and human CD8+CD45RA− T cells datasets from a and f, respectively
(p adj < 0.1). Highlighted are concordantly expressed genes associated with Tc17 or CTL phenotype. h Heatmap of top transcripts with correlating expression
in murine Tc17 and human CD8+CD45RA− T cell-datasets from a, f, respectively. DE mouse Tc17 transcripts (p adj < 0.01, log2Fc≥ 0.6), and corresponding
182 human transcripts with GSEA core enrichment were selected. Highlighted are genes associated with Tc17 and CTL phenotype. i Relative expression of
RORC-to-TBX21 calculated from RNA-seq from f. j GSEA of genes associated with ROS-signaling in human CD8+CD45RA− T cells from f based on
MSigDBv6.1. k, l GSEA of genes associated with IL17+CD8+ k or IL17−CD8+ l proﬁles in CD8+CD45RA− T cells from f based on published raw data (RNA-
Seq GSE96741)42. Bars show mean ± s.d. from four to three b, c, i combined experiments; individual values are plotted. In b, c *p < 0.05, ***p < 0.001
evaluated by one-way ANOVA followed by Tukey’s HSD multiple comparison test, in i p-value by the two-tailed, unpaired t-test.
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Fig. 3 DMF enhances PI3K-AKT-T-BET-signaling to diminish IL-17 and RORγt in Tc17 cells. a GSEA examining the enrichment of genes associated with
PI3K-AKT-mTOR-signaling in human CD8+CD45RA− T cells upon stable response to DMF therapy based on MSigDBv6.1 (dataset from Fig. 2f). b Flow
cytometry of IL-17A in murine Tc17 cells differentiated for 72 h ± DMF, ± 1 µM Ly294002 (fold IL-17A induction by Ly294002, a PI3K inhibitor). c, d Flow
cytometry of P-AKT(S473) c and P-AKT(T308) d in murine Tc17 cells differentiated for 48 h ± DMF, DMF+GSH, ± 1 µMAKTi (AKT-1/2 inhibitor) or DMF+
AKTi. e Flow cytometry of P-FOXO1(T24)/FOXO3a(T32) in Tc17 cells differentiated for 48 h ± DMF or DMF+GSH. Bars to the right in c, d, and e show fold
MFI normalized to the respective control, which was arbitrarily set to 1. f Heatmap of color-coded z-scores from the rlog transformed, batch-corrected FOXO1
target genes according to Michelini et al44 in Tc17 cells, (dataset from Fig. 2a). g Flow cytometry for IL-17A and IFN-γ in WT and Tbx21−/− Tc17 cells
differentiated for 72 h with indicated treatment (fold IL-17A induction by AKTi). h Flow cytometry for RORγt in WT and Tbx21−/− Tc17 cells differentiated
for 72 h with indicated treatment. Bars show fold RORγt expression (MFI normalized to respective control, which was arbitrarily set to 1). i Flow cytometry
for IL-17A in WT and Tbx21−/− Tc17 cells differentiated for 72 h (fold IL-17A inhibition by DMF). Bars show mean ± s.d. from six c, ﬁve to four b, d, e and
g–i combined experiments; individual values are plotted. In b, g, i *p < 0.05, **p < 0.01 evaluated by two-tailed, unpaired t-test, in h *p < 0.05 by two-tailed
unpaired t-test with Welch’s correction, in (d and e) *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA followed by Tukey’s HSD multiple comparison
test, in c *p < 0.05, **p < 0.01, ***p < 0.001 by one-way Welch’s ANOVA with Games-Howell multiple comparison test.
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associate with MS3,5, (iii) increased IL-17A mRNA levels are
detectable in MS52 and (iv) IL-17 contributes to disruption of
blood–brain–barrier tight junctions53. Furthermore, the ther-
apeutic targeting of IL-17A by the fully humanized antibody
secukinumab is successful in psoriasis54, rheumatoid arthritis55
and ankylosing spondomyelitis56, as well as there are promising
results in a proof-of-concept study in MS57. Here, we demon-
strate that a positive response to DMF therapy associates with a
reduction in Tc17, in contrast to Th17 cells, in MS. Furthermore,
in patients with a positive response to the therapy, DMF modiﬁed
Tc17 transcriptional proﬁle towards a “CTL-like” signature.
Indeed, DMF inhibited IL-17 production in human Tc17 cultured
in vitro, indicating its direct effect. Similar pattern of response to
DMF was observed in murine Tc17 cells, revealing a comparable
regulation across species and thus allowing mechanistic and
functional experiments. In the mouse model, oral DMF treatment
in therapeutic as well as in preventive setting ameliorated clinical
signs of disease and suppressed frequency of IL-17-producing
CD8+ T cells in CNS, consistent with the results obtained from
PB of MS patients. In the adoptive transfer model, the
amelioration of the disease by DMF was caused by a stable
suppression of Tc17 cells and thereby loss of their co-pathogenic
function resulting in the reduced frequency of Th17 cells in the
CNS. This is consistent with previous reports showing reduced
frequencies of Th17 cells in DMF-treated mice26,28. Immune
modulatory effects of DMF also include inﬂuence on IFN-γ
production by CD4+ T cells26,28, as well as on the phenotype of
dendritic cells, monocytes26,29,32 and metabolism of macro-
phages28, which likewise contribute to the therapeutic effect.
Considering multiple mechanisms driven by DMF and an
extensive heterogeneity in the disease course resulting from dis-
tinct effector mechanisms underlying MS1, we believe that our
ﬁndings and conclusions apply to a subset of patients, in which
Tc17 cells are involved in the disease pathogenesis. This idea is
supported by our ﬁnding that the mean frequency of Tc17 cells
before DMF therapy was signiﬁcantly higher in responders as
compared to non-responders however, further studies should
prove this concept.
In MS patients the majority of IL-17-producing CD8+ T cells
expresses the molecules CD161 and CCR6, as well as TCRVα7.2,
a d
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characterizing them as MAIT cells16,17,19. Functionally, these cells
seem to have pathogenic relevance since pediatric MS patients
harbored more IL-17-producing MAIT cells in PB, as compared
to healthy controls or children with monophasic inﬂammatory
CNS disorder18. Furthermore, increased IL-17 production by
MAIT cells20 as well as their enhanced accumulation in brain
lesions19 was detectable in MS. Considering these reports, it is
possible, that the DMF-mediated reduction of IL-17 producing
CD8+ T cells in MS patients, which we herein described, may also
affect CD161high CD8+ MAIT cells. As MAIT cells were not
affected by IFN-β therapy, but strongly reduced by high dose of
cyclophosphamide in combination with alemtuzumab treatment
followed by autologous stem cell transplantation in MS patients17,
one can speculate that besides the non-myeloablative depletion,
MAIT cells might be susceptible to ROS upregulated by DMF-
mediated glutathione depletion. Therefore, it will be of interest
for future studies to compare in detail the susceptibility to DMF
of conventional versus CD161high CD8+ MAIT Tc17 cells in
patients, to deﬁne the main target population within IL-17-
producing CD8+ T cells and to closely characterize the therapy
responder group.
The idea of DMF-mediated diversion of Tc17 proﬁle towards a
“CTL-like” genetic signature is based on the comparison of
memory CD8+ T cells from untreated versus treated MS patients
with IL-17+CD8+ versus IL-17−CD8+ T cell from healthy
individuals, which proﬁles were recently published42, as well as
with our datasets on gene expression in mouse effector Tc17.
Importantly, for the gene expression proﬁles of human IL-17
+CD8+ and IL-17−CD8+ T cells, MAIT and γδT cells were
excluded42, suggesting that the DMF-mediated diversion from
Tc17-like towards “CTL-like” proﬁle relates rather to “classical”
Tc17 cells. The diversion was accompanied by a decreased ratio of
RORγt-to-T-BET, transcriptional regulators governing the
development of type 17 or CTL, respectively. This indicates that
DMF not only simply inhibited IL-17, but suppressed the tran-
scriptional program governing Tc17 differentiation in favor of T-
BET and CTL-associated genes. DMF-mediated upregulation of
T-BET crucially contributed to this effect, as T-BET opposes Tc17
differentiation22,24 and RORγt58 expression. Our work further
unraveled the molecular pathway of DMF mediated T-BET
upregulation, which included enhanced AKT activation, accom-
panied by FOXO1 phosphorylation and inactivation, leading to
upregulation of T-BET. Accordingly, T-BET deﬁciency in Tc17
cells led to decreased response to DMF with respect of IL-17
production and RORγt downregulation. These data reveal T-BET
as an important DMF target in Tc17 cells, suppressing IL-17
production and RORγt expression. In line with our data, a pre-
vious report demonstrated signiﬁcantly reduced TBX21 expres-
sion in MS patients compared to healthy controls59, pointing to
an association of low TBX21 levels with the disease. Therefore, we
surmise that upregulation of TBX21 with concomitant down-
regulation of RORC in CD8+ T cells by DMF contributes to its
therapeutic efﬁcacy in MS. Further studies might support this
speculation.
In addition to the PI3K-AKT-T-BET pathway, enhanced
STAT5 activity contributed to DMF-mediated suppression of IL-
17, in which STAT5 limited IL-17 production in Tc17 cells in a
similar manner as described for Th17 cells48. The STAT5 or PI3K-
AKT activity-enhancing function by glutathione-depletion has not
been described for T cells so far, but upregulated ROS enhanced
STAT5-phosphorylation and PI3K-AKT-activity in hepatocytes in
the context of obesity and type II diabetes60 or cancer cells61,62.
Considering that upregulated ROS can inhibit phosphatase
activity, as demonstrated for the protein-tyrosine phosphatase
PTPN2 in hepatocytes60 and for PTEN in macrophages62, it is
conceivable that the increased phosphorylation of PI3K-AKT-
FOXO1 and STAT5 is caused by a similar mechanism in Tc17
cells. DMF-signaling led to suppression of the permissive histone
state on Il17 locus, ultimately restricting IL-17. Notably, and in
contrast to STAT5, AKT-mediated suppression of IL-17 produc-
tion took place in Tc17 but not in pathogenic Th17 cells. This
indicates common (STAT5) and differential signaling pathways
(AKT) regulating IL-17 in Tc17 and Th17 cells. Furthermore,
Tc17 and Th17 cells seem to differ in respect to utilized energy
supply. Whereas Th17 cells strongly depend on glycolysis39, Tc17
cells were refractory to 2-DG treatment, instead they seem to rely
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on OXPHOS as examined by sensitivity to inhibitors rotenone and
oligomycin. Hence, our data indicate cell-type-speciﬁc signaling
pathways controlling IL-17 production, which could explain
particular responsivity of Tc17 to DMF treatment. This is in
agreement with a recent publication demonstrating speciﬁc
transcriptional programs for mouse and human Tc17 and Th17
cells42.
Overall, we provide mouse and human data that support a
concept for DMF mode of action in MS that may endorse
development of drugs targeting the delineated signaling pathways.
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The described mechanisms can be extended to other IL-17-
mediated diseases, where CD8+ T cells are a cellular source,
including psoriasis or tumorigenesis to develop comprehensive
therapy strategies.
Methods
Study design and participants. Patients visiting the Center of Neuroimmunology
of the University of Marburg and at the Department of Neurology at the University
of Mainz between 2014–2017 were offered standard immunotherapies according to
national treatment guidelines and followed longitudinally in an observational
cohort. Key eligibility criteria included age of 18 to 57 years, a diagnosis of MS
(according to the 2010 McDonald criteria63), an Expanded Disability Status Scale
(EDSS) score of 0 to 4.0 at the start of DMF therapy (score range from 0 to 10.0
with higher scores indicating a greater degree of disability), maximum one prior
short-term therapy with IFN-β or glatiramer acetate to minimize effects on
immune system and the ability to give informed consent. The key exclusion criteria
were a diagnosis of primary progressive multiple sclerosis, prior therapies with
monoclonal antibodies or immunosuppressive medications, disease duration of
more than 2.5 year since diagnosis. Blood was collected immediately prior to
treatment initiation and approx. one year later. Patients were followed long-
itudinally and stratiﬁed into two groups according to treatment response (Tecﬁ-
dera, 240 mg per os twice a day) deﬁned as NEDA-3 positive or negative status
under an appropriate treatment period with DMF (re-baselining 4 months after
treatment start). NEDA-3 is a composite score deﬁned as: (i) no relapses, (ii) no
sustained disability progression measured with EDSS and (iii) no new/enlarging
T2-weighted lesions in magnetic resonance imaging (MRI)37. In total, 65 patients
were included in the study cohort, compromising 40 responders and 25 non-
responders. 3 non-responders were excluded as therapy was escalated due to dis-
ease activity after 4 months after treatment initiation. In agreement with DMF
clinical efﬁcacy, more patients were included into the responder group (n= 40). To
exclude a selection bias and to obtain comparable group sizes, propensity score
matching 1:1 to responders and to non-responders based on age, gender, MS
duration since diagnosis and EDSS before treatment was performed. If multiple
qualiﬁed patients were available for matching, random selection was employed.
Selected (n= 21) and excluded (n= 19) responders did not differ concerning
above mentioned parameters. From the measured 21 DMF-responder samples,
3 samples were excluded, while from 22 non-responder samples, 4 samples were
excluded, all because of low cellularity within the primary sample (Supplementary
Fig. 7).
Since NEDA-3 reﬂects therapeutic efﬁcacy, patients, who were NEDA-3 positive
were termed responders (n= 18), whereas NEDA-3 negative patients were termed
non-responders (n= 18), (Supplementary Tables 1–3). All responders were not
treated with any disease modifying therapy before initiation of DMF therapy
(“treatment naïve”) except of a standard of care short-term high dosage steroid
treatment (1000 mg methylprednisolone for 5 consecutive days), leading to
symptom recovery. Blood was drawn 8 weeks after discontinuing from steroid
treatment as a baseline and then after 12 months of DMF treatment, a time point of
a clear clinical and immunological response to the drug64,65. The non-responder
group comprised of 10 treatment naïve MS patients and 8 patients with previous
therapy: 6 patients were treated with IFN-β-1a (44 µg s.c., 3 times a week) for 0.5–2
years, whereas 2 patients received glatiramer acetate for 2–6 months (20 mg s.c.,
daily) before initiation of DMF therapy. Previous therapy was discontinued because
of disease activity or side effects. DMF treatment was initiated 6 to 8 weeks later.
The lymphocyte counts were in the normal range ( > 1200 µl−1 PB) at the time-
point of DMF therapy initiation. Blood was drawn as a baseline, 8 weeks after
discontinuing from steroid treatment for treatment naïve patients, while for
patients with previous therapies blood was drawn 6 to 8 weeks after discontinuing
from IFN-β-1a or glatiramer acetate therapy. The second blood sample was drawn
at the time point of disease progression deﬁned by NEDA-3 criteria, mean for 18
patients: 10.8 months (Supplementary Tables 1–3). The study was conducted
according to the rules of the Declaration of Helsinki. It was approved by the Ethics
Committees of the University of Marburg and Mainz and all included patients gave
written informed consent.
Stimulation and staining of PBMCs from MS patient. Peripheral blood mono-
nuclear cells (PBMCs) were obtained from blood, which were subsequently frozen.
Then, PBMCs were thawed, rested in pre-warmed RPMI/5% AB serum for 2 h,
followed by restimulation with PMA (50 ng ml−1)/Ionomycin (1 µg ml−1), for 2.5 h
and with addition of brefeldin A (5 µg ml−1) for further 2.5 h. The cells were
stained with: Zombie NIR ﬁxable viability kit (#423106), anti-CD8a (SK1), anti-
CD4 (RPA-T4), anti-CD14 (HCD14), anti-CD45RA (HI100), anti-IL-17A (BL168),
all from Biolegend. Gated CD14−CD4−CD8+CD45RA− or CD14−CD8−CD4+
CD45RA− cells were analyzed for IL-17 on Aria III using Diva software (v8.0.2.).
Gating strategy is included in Supplementary Fig. 1b. To control batch effects and
day-to-day variations frozen PBMCs were used. For this, blood from a healthy
donor was drawn, processed for PBMC isolation and then frozen in several aliquots
which served as control samples. The control samples were thawed, rested, resti-
mulated, ﬁxed, stained, acquired and analyzed at the start of responder sample
analysis (time point I) and then at two different days (time points II and III, for
non-responder analysis) using the same standard protocols, by the same person.
The analysis reveals a very similar outcome, which gives mean for Tc17 frequency:
0.283 ± 0.0153 ( ± sd) (Supplementary Fig. 8).
Patient data analysis. The analysis of IL-17 production by memory CD4+ and
CD8+ T cells from PBMCs of MS patients before and after DMF therapy, who
responded (NEDA-3 positive) or did not (NEDA-3 negative) to DMF was blinded
and based on following power analysis. We performed power calculations, extra-
polating from in vitro pilot experiments (IL-17 production by human memory
CD8+ T cells ± DMF treatment) to a patient estimate (Supplementary Fig. 1d).
We called relevant a difference of post-pre-DMF-treatment of 1.5 and detected
a SD of 1.2 for the differences. With a signiﬁcance level of alpha= 0.05 and an
available patient pool of n= 18 (paired design, assuming normally distributed
values), we would expect to obtain a power of about 95%.
We evaluated P values for changes in the frequency of CD8+CD45RA−IL-17+
cells through DMF therapy for each patient (n= 1;…;18, responder and non-
responder), within the respective group, using two-tailed, paired t-tests (P values
shown above the groups, Fig. 1a). To compare the changes in the frequency of CD8+
CD45RA−IL-17+ cells through DMF therapy between responder and non-responder
groups a two-tailed, unpaired Student’s t-test was applied (P value shown between
groups, Fig. 1a). The change (Δ) in the frequency of CD8+CD45RA−IL-17+ cells
through DMF therapy, was calculated by subtracting the percentage of CD8+
CD45RA−IL-17+ cells before DMF therapy (X1) from the percentage of CD8+
CD45RA−IL-17+ after therapy (X2) for each patient (Δ=X2−X1). The same
calculation was performed for the inﬂuence of DMF therapy on the frequency of
CD4+CD45RA−IL-17A+ T cells. P values were determined using GraphPad version
8.0 software.
Stimulation of CD8+ T cells from healthy donors. PBMCs from healthy donors
were enriched by performing ﬁcoll gradient centrifugation and then labeled with
anti-CD8a (PRA-T8; BioLegend), anti-CD4 (OKT-4; BioLegend) and anti-
CD45RA (HI100; BioLegend). CD8+CD45RA− cells were sorted using a FAC-
SAria™ III. Tc17 cells were stimulated with anti-CD3 (2 μg ml−1, clone TR66) and
anti-CD28 (2 μg ml−1 CD28.2; BD Biosciences) in the presence of rh IL-1β 20 ng
ml−1, rh TGF-β 20 ng ml−1, rh IL-6 10 ng ml−1, rh IL-2 50 Uml−1. Tc17 cells were
treated with 0.1% DMSO as a control, or with 10 μMDMF alone or in combination
with 50 μM GSH. Living cells were analyzed by ﬂow cytometry for IL-17A Paciﬁc
Blue, anti-IL-17A (BL168; Biolegend) and IFN-γ APC-Cy7 anti-IFN-γ (4 S.B3;
BioLegend) production after 4 days of culture and restimulation with PMA/
ionomycin for 2.5 h and brefeldin A for further 2.5 h. Supernatants were collected
after 4 days and IL-17 was measured with the Human IL-17 DuoSet ELISA (R&D,
DY317).
Mice. WT C57BL/6 were purchased from The Jackson Laboratory. Irf4−/−,
Tbx21−/−, 2D2 mice expressing a transgenic TCR speciﬁc for MOG35–55 and
CD45.1+ mice were bred at the Biomedical Research Center, University of Mar-
burg. All mice were 8–12 weeks old, at C57BL/6 background and sex- and age-
matched.
Murine T cell puriﬁcation and in vitro differentiation. CD4+ or CD8+ T cell
were obtained from LNs and spleens using negative selection kits (130–104–454 or
130–104–075) both from Miltenyi. For some experiments, CD4+ or CD8+T cells
were sorted on Aria III (BD Biosciences) to obtain naïve CD44−CD62L+CD4+ or
CD44−CD62L+CD8+T cells using anti-CD4V450 (RM4–5, BD Biosciences) or
anti-CD8V500 (53–6.7, BD Biosciences), anti-CD44PE (IM7, eBiosciences) and
anti-CD62LAF700 (MEL-14, BD Pharmingen) mAbs. Doublets were excluded
through forward scatter-height by forward scatter-width and side scatter-high by
side-scatter width parameters. Sorting purity was > 97% in post-sort analysis.
Gating strategy is provided in Supplementary Fig. 9a. Tc17 were primed in RPMI
(10%FCS) with plate-bound anti-CD3 mAb (5 µg ml−1) and soluble anti-CD28
(0.5 µg ml−1, both produced ‘in-house’), rhIL-2 (50 Uml−1, Novartis), rhTGF-β
(0.5 ng ml−1, Peprotech) rmIL-6 (30 ng ml−1, Peprotech) and anti-IFN-γ
(5 µg ml−1, produced ‘in-house’). For Th17 cell priming the conditions were used
as for Tc17 cells with addition of rmIL-23 (20 ng ml−1, Peprotech). Used inhibi-
tors: DMF (Sigma-Aldrich, 242926, 20 µM), GSH (Sigma-Aldrich, G1404, 50 µM),
Trolox (Merck Milipore, 648471, 400 µM), 2-DG (Millipore, 25972, 250 µM),
rotenone (Sigma, R8875, 10 nM), oligomycin (Sigma, 04876, 15 nM) Akt1/2inhi-
bitor (Akti, Merck Milipore, 124018, 1 µM), STAT5 inhibitor (STAT5i, Cayman,
15784, 35 µM), Ly294002 (Cell Signaling, 9901, 1 µM), TSA (Sigma-Aldrich,
T8552, 1 nM) and rapamycin (Cell Signaling 9904, 50 nM).
Flow cytometry. For intracellular cytokine staining, murine cells were restimulated
after 72 h of culture with PMA (50 ng ml−1), Ionomycin (1 µg ml−1, both from
Sigma-Aldrich) and brefeldin A (5 µg ml−1; Biolegend) for 4 h and ﬁxed with 2%
para-formaldehyde. Staining of transcription factors was performed without res-
timulation using the FOXP3/Fixation-Kit (eBioscience, 00–5521–00). Following
antibodies were used for murine cell-analysis: anti-CD8a (eBiosciences, 53–6.7),
anti-CD44 (eBiosciences, IM7), anti-CD62L (eBiosciences, MEL-14), anti-IFN-y
(Biolegend, XMG1.2), anti-IL-17A (eBiosciences, eBio17B7), anti-RORyt
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(eBiosciences, B2D) or anti-T-BET (eBiosciences, eBio4B10). The cells were mea-
sured on FACSCalibur or FACSAria™ III (both BD) and analyzed with FlowJo
Software (FlowJo LLC). For phospho-ﬂow the cells were harvested after 48 h of
culture, rested for 4 h and treated with 100U/ml rhIL-2 for 2 h, ﬁxed and per-
meabilised using Lyse/Fix-Buffer (557870, BD) and Perm-BufferIII (558050, BD)
then stained with anti-P-STAT5Y694 (eBiosciences, SRBCZX), anti-P-AKTS473
(Cell Signaling, D9E), anti-P-AKTY308 (Cell Signaling, D25E6), anti-P-FOXO1/3a
(Cell Signaling, #9464) or anti-P-S6S235/236 (Cell Signaling, D57.2.2E).
GSH Assay and ROS quantiﬁcation. Tc17 or Th17 cells were differentiated for
2 h ± DMF or DMF+GSH. Then, cells were washed and GSH/GSSG Glo™ Assay
(Promega, V6611) was used or ROS levels were determined by incubation with
1 µM chloromethyl derivative of 2’,7’-dichlorodihydroﬂuorescein diacetate (CM-
H2DCFDA, Thermo Fisher Scientiﬁc, C6827) according to the manufacturer’s
instructions.
Extracellular Flux Assay. For extracellular ﬂux assay, CD8+ cells were puriﬁed
and differentiated to Tc17 cells for 3 days in the presence of DMSO or 20 µM DMF.
On the day of assay 3–4 × 105 in vitro differentiated Tc17 cells were plated per well
(n= 6) in a 96-well Seahorse plate in Assay media (Glucose-free DMEM supple-
mented with 2 mM glutamine, 1 mM NaCl, 0.5% phenol red, pH 7.35) in oxygen-
free conditions. After 2 h of pre-incubation extracellular acidiﬁcation rate (ECAR)
was measured at baseline and in response to 10 mM glucose, 2.5 µM oligomycin
and 100 mM 2-deoxy-D-glucose (2-DG) according to the manufacturer’s protocols
using the XF-96 Extracellular Flux Analyzer (Agilent).
RNA-Seq and bioinformatics of murine Tc17 cells. Tc17 cells obtained from
naive CD62L+CD44−CD8+ cells were cultured ± DMF or DMF+GSH for 48 h,
then RNA was puriﬁed from Extrazol according to the manufacturer’s speciﬁca-
tions. RNA was puriﬁed with the RNeasy Plus Mini Kit according to the manu-
facturer’s protocol (Qiagen). RNA was quantiﬁed with a Qubit 2.0 ﬂuorometer
(Invitrogen) and the quality was assessed on a Bioanalyzer 2100 (Agilent) using a
RNA 6000 Nano chip (Agilent). Samples with an RNA integrity number (RIN) of
>8 were used for library preparation. Barcoded mRNA-seq cDNA libraries were
prepared from 400 ng of total RNA using NEBNext® Poly(A) mRNA Magnetic
Isolation Module and NEBNext® Ultra™ RNA Library Prep Kit for Illumina®
according to the manual. Quantity was assessed using Invitrogen’s Qubit HS assay
kit and library size was determined using Agilent’s 2100 Bioanalyzer HS DNA
assay. Barcoded RNA-Seq libraries were onboard clustered using HiSeq® Rapid SR
Cluster Kit v2 using 8 pM and 50 bps were sequenced on the Illumina HiSeq2500
using HiSeq® Rapid SBS Kit v2 (50 Cycle). The raw output data of the HiSeq was
preprocessed according to the Illumina standard protocol. Quality control on the
sequencing data was performed with the FastQC tool (available at http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/), as well as the comprehensive
Qorts suite. Inspecting the produced reports, all samples were deemed of good
quality for further processing. Short reads alignment was performed with the
ENSEMBL Mus_musculus.GRCm38 chosen as the reference genome. The corre-
sponding annotation (ENSEMBL v76) was also retrieved from the ENSEMBL FTP
website (http://www.ensembl.org/info/data/ftp/index.html). The STAR66 aligner
(version 2.4.0b) was used to perform mapping to the reference genome. Alignments
were processed with the featureCounts67 function of the Rsubread package, using
the annotation ﬁle, also used for supporting the alignment. Exploratory data
analysis was performed with the pcaExplorer package. Differential expression
analysis was performed with DESeq2 package (version 1.18.1), setting the false
discovery rate (FDR) to 0.01. The GLM framework of the DESeq2 R68 package was
applied, accounting for the sample preparation batch as a confounding factor in the
model to increase the detection power. Gene expression proﬁles were plotted as
heatmaps (color-coded z-scores for the regularized logarithm (rlog) transformed
batch-corrected expression values.) with the R programming language and the
pheatmap package (version 1.0.8). GSEA was performed as described41. Principal
component analysis was performed using the pcaExplorer package (V2.5.1)69.
Patient cohort for transcriptome analysis. To avoid individual-related differ-
ences we analyzed a matched cohort of 8 persons with MS diagnosed according to
the McDonald criteria63, which were stratiﬁed in two groups (Supplementary
Fig. 2b): The ﬁrst group termed “DMF untreated” consisted of 4 patients who were
not treated with DMF before. In this group, three patients were treatment naive,
meaning no treatment with any drug before, except of a short-term high dosage
steroid treatment (1000 mg methylprednisolone for 5 consecutive days). Blood was
drawn 8 weeks after discontinuing from steroid treatment. One patient was treated
with Fingolimod (0.5 mg p.o daily) for four months and discontinued due to
patient´s wish. Blood was drawn 6 months after Fingolimod discontinuation, at
this time point the lymphocyte counts were in the normal range ( > 1200 µl−1 PB).
After blood collection, DMF therapy was initiated. The second group, termed
“DMF treated” consisted of 4 patients who fulﬁlled NEDA-3 criteria after
12–13 months of DMF treatment (240 mg p.o twice a day). Before initiation of
DMF therapy two patients were treatment naive, except of a short-term high
dosage steroid treatment. DMF therapy was initiated 8 weeks after steroid dis-
continuation. Two patients were treated with IFN-β-1a (44 µg s.c., 3 times a week)
for 2–2.5 years before initiation of DMF therapy. One patient was discontinued
from IFN-β 1a due to depression, whereas the second because of incompliance due
to ﬂu-like side effects. DMF therapy was initiated 4 to 6 months later. The lym-
phocyte counts were in the normal range ( >1200 µl−1 PB) at the time-point of
DMF therapy initiation (patient characteristics are included in Supplementary
Table 4). The PCA based on RNA-Seq data, revealed that the two group of patients
(i) “DMF untreated” versus (ii) “DMF treated” clearly separate on the PC1 (Sup-
plementary Fig. 2c). Since PC1 follows the treatment axis, the main driver of
differences between these two groups was DMF treatment. This cohort was col-
lected at the Department of Neurology at the University of Mainz. The study was
conducted according the rules of the Declaration of Helsinki. The Ethics Com-
mittee of the University of Mainz provided approval for this study and blood
samples blood was drawn after written informed consent was obtained.
RNA-Seq of human CD8+ T cells from MS patients. Fresh PBMCs from MS
patients “DMF untreated” (n= 4) and “DMF treated” (n= 4) fulﬁlling NEDA-3
criteria after 12–13 months of DMF (Tecﬁdera) treatment (240 mg p.o twice a day)
(Supplementary Table 4 and Supplementary Fig. 2b) were labeled with anti-CD8a-
BV510 (SK1), anti-CD4-Pacifc Blue (RPA-T4), anti-CD14-FITC (HCD14), anti-
CD45RA-BV650 (HI100), Zombie NIR; all from Biolegend. Memory CD8+ T cells
(CD8+CD45RA−) were sorted on FACSAria™III (BD Biosciences). Gating strategy
is provided in Supplementary Fig. 9b. RNA was isolated using RNeasy plus micro
kit (Qiagen), quantiﬁcation, library preparation by using 20 ng of total RNA,
sequencing (QC via FastQC and Qorts) was performed as described for mouse
Tc17 cells. Sequencing reads were aligned with STAR (2.4.0j) to the ENSEMBL
Homo_sapiens.GRCh38 reference genome, with annotation ENSEMBL v79.
Similarly, the count matrix was obtained with featureCounts (Rsubread package).
Differential expression analysis was performed with DESeq2 package (version
1.20), modeling the patient condition as only experimental factor (FDR= 0.01).
Human IL-17+CD8+ and IL-17−CD8+ T cell gene signatures. The RNA-Seq
data (raw counts) from human IL-17+CD8+ and IL-17−CD8+ spleen cells from
healthy donors was downloaded from the NCBI Gene Expression Omnibus under
the accession number GSE96741. The contrast IL-17+CD8+ versus IL-17−CD8+
was calculated using the DESeq2 package68, loaded from Bioconductor(version
3.9), with R (free software, version 1.1.423, Rstudio Inc v3.6). The differentially
expressed genes (p adj < 0.05), grouped into up- and down-regulation, were
extracted as IL-17+CD8+ or IL-17−CD8+ gene signatures.
Retroviral transduction. Freshly isolated naïve CD8+ T cells were plated in a 48-
well plate (3 × 105 cells per well), 500 µl of retroviral supernatant with constitutive-
active STAT5A1*6 (pMIG-STAT5)70, or a control retrovirus (pMIG-empty) con-
taining 7 µg ml−1 polybrene and 50 Uml−1 rhIL-2 was added and the cells were
spun at 2700 rpm for 90 min at 37 °C. After spin infection, the cells were cultured
under Tc17 conditions ± DMF for 2 h, then the cells were transfected for a second
time as before, then cultured under Tc17 conditions ± DMF for 72 h, rested in
RPMI+ rhIL-2 and anti-mIFN-y for further 72 h. Thereafter, the cells were re-
cultured under Tc17 conditions for additional 72 h, then restimulated and analyzed
by ﬂow cytometry.
Chromatin immunoprecipitation. Tc17 cells were cultured for 72 h ± DMF or
DMF+GSH as indicated in Figure legends. 2–5 × 106 cells were crosslinked with
1% formaldehyde for 6 min at room temperature subsequently, ChIP was per-
formed. Lysed cells were sonicated in a Bioruptor® Plus (Diagenode) with 30s ON,
30s OFF on high power output for 27–33 cycles at 4 °C. For immunoprecipitation,
2.5–4 µg of the following Abs were used: anti-H4ac (Millipore, 06–866), anti-
H3K4me3 (Active Motif, 39159), anti-H3K27me3 (Active Motif, 39155), anti-
H3K27ac (Abcam, ab4729) or control IgG (Cell Signaling, 2729). Primer sequences
for Il17a promoter, Il17 enhancer-5, Il10 promoter and Rpl32 are provided in
Supplementary Table 5. Ampliﬁcations were performed at the ABI Prism7500
(Applied Biosystems) using the Fast SYBR™Green (Thermo Fisher, 4385610).
Values for non-speciﬁc binding (determined by control IgG) were subtracted. After
normalization, the speciﬁc pulldown (input %) was calculated.
Nuclear extraction and immunoblot. Tc17 cells were differentiated for 72 h in the
presence of DMSO ± 20 µM DMF ± 50 µM GSH. Cytosolic and nuclear lysates were
produced using (10 mM HEPES pH7.9, 10 mM KCl and 1.5 mM MgCl2) and (2%
SDS and 66 mM Tris–HCl pH7.0), respectively. The following Abs were used: anti-
H4Ac (Millipore, 06–866), anti-H3K4me3 (Active Motif, 39159), anti-H3K27me3
(Active Motif, 39155) and anti-H3K27Ac (Abcam, ab4729).
EAE. For induction of active EAE, C57BL/6 mice were immunized s.c. at the tail
basis with 50 μg MOG35–55 peptide (GenScript) emulsiﬁed in Complete Freund’s
adjuvant (CFA, BD) along with 100 ng pertussis toxin (PTX, List-Biological-
Laboratories) administration i.p. on day 0 and 2. For therapeutic treatment, DMF
was given daily (10 mgml−1) by oral gavage26 in an emulsion 0.6% Methocel
(methylcellulose, Sigma-Aldrich, M0262). Control animals were treated with 0.6%
Methocel vehicle alone. Treatment started at day 8, after all animals exhibited
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initial symptoms of EAE. For preventive treatment, DMF was applied by supplying
the drinking water with 0.5 mg ml−1 DMF 10 days before immunization. For
adoptive transfer experiments 2.5 × 106 Tc17 ± DMF cells/mouse were injected i.p.
± 2D2 cells (103 cells per mouse) into Irf4−/− recipient mice one day before
immunization. Daily clinical scoring of EAE symptoms was conducted as follows:
0, no symptoms, normal behavior; 1, tail paralyzed; 2, impaired righting reﬂex and
gait; 3, partial hind limb paralysis; 4, hind legs completely paralyzed; 5, tetraparesis
6, dead. For the preparation of CNS lymphocytes, brains and spinal cords were
excised and were dissociated for 40 min at 37 °C by digestion with collagenase D
(0.5 mg/ml) and DNase I (10 μg/ml; both from Roche) in RPMI medium. Dis-
persed cells were passed through a 70-μm strainer and were pelleted by cen-
trifugation, then were resuspended, layered onto a Percoll density gradient (GE
Healthcare) and centrifuged for 30 min at 625 g and 22 °C. CNS lymphocytes were
isolated by collection of the interphase fraction between 40% and 70% Percoll.
After intensive washing in complete RPMI, cells were restimulated in vitro and
were analyzed by ﬂow cytometry. The cells were analyzed at the peak of disease
(day 14–17 after immunization) for CD8a, CD4, CD45.1 (Biolegend, A20), IL-17A
and IFN-y by ﬂow cytometry.
Statistical analysis. Statistical analysis was performed using the GraphPad version
8.0 software. Data are presented as mean ± s.d. For all data sets, normality of
distribution and homogeneity of variances was evaluated by Shapiro–Wilk test and
Brown–Forsythe, respectively to test for violations of the assumptions inherent to
parametric signiﬁcance testing. None of the data sets showed signiﬁcant departure
from normality in the Shapiro–Wilk test. Statistical signiﬁcance to compare two
groups was evaluated using two-tailed/unpaired t-tests. In case of signiﬁcant dif-
ferences in variances between groups, Welch's correction was applied. The con-
ﬁdence interval was 95%. For multiple groups and/or multiple condition
comparisons one-way or two-way analysis of variance (ANOVA) was performed
followed by a Tukey’s HSD, Dunnett’s or Bonferroni post hoc test, respectively. In
case of signiﬁcant differences in variances between groups, Welch´s ANOVA with
Games–Howell multiple comparison test was applied. A critical value for sig-
niﬁcance of P < 0.05 was used throughout the study, and statistical thresholds of
0.01, 0.001, as well as 0.0001 are indicated in the ﬁgures by asterisks (see legends for
details). The exact P values, for ANOVA F values; for Welch’s ANOVA, W values;
t-test: t-values and degrees of freedom are provided in Supplementary Table 6 for
main Figures and in Supplementary Table 7 for Supplementary Figures.
Study approval. All patients and controls gave their written informed consent
after the Universities of Marburg and of Mainz IRB approval. Mouse experiments
were approved by the local committee (Regierungspräsidium Gießen).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data sets generated during and/or analyzed during the current study are available
from the corresponding author on reasonable request. Sequencing data have been
deposited in the Gene Expression Omnibus (GEO). The sequencing data is available
under following accession numbers: the murine Affymetrix microarray data for CTL and
Tc17 proﬁles: GSE110346, the murine RNA-seq data of Tc17 cells treated with DMSO,
DMF or DMF+GSH: GSE116866, and the human data of MS patients before and after
12 months of DMF treatment: GSE116865.
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